Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Duvelisib is an oral dual inhibitor of phosphoinositide 3-kinase-δ (PI3K-δ) and PI3K-γ in late-stage clinical development for hematologic malignancy treatment. This phase 1 study evaluated maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics (PD), efficacy, and safety of duvelisib in 210...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood
Egile Nagusiak: Flinn, Ian W., O’Brien, Susan, Kahl, Brad, Patel, Manish, Oki, Yasuhiro, Foss, Francine F., Porcu, Pierluigi, Jones, Jeffrey, Burger, Jan A., Jain, Nitin, Kelly, Virginia M., Allen, Kerstin, Douglas, Mark, Sweeney, Jennifer, Kelly, Patrick, Horwitz, Steven
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2018
Gaiak:
Lymphoid Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6033052/
https://ncbi.nlm.nih.gov/pubmed/29191916
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-05-786566
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak